1. Home
  2. MSB vs NNNN Comparison

MSB vs NNNN Comparison

Compare MSB & NNNN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Mesabi Trust

MSB

Mesabi Trust

N/A

Current Price

$19.60

Market Cap

301.2M

ML Signal

N/A

Logo Anbio Biotechnology Class A Ordinary Shares

NNNN

Anbio Biotechnology Class A Ordinary Shares

N/A

Current Price

$6.30

Market Cap

270.4M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
MSB
NNNN
Founded
1961
2021
Country
United States
Germany
Employees
N/A
N/A
Industry
Metal Mining
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Basic Materials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.2M
270.4M
IPO Year
1995
2023

Fundamental Metrics

Financial Performance
Metric
MSB
NNNN
Price
$19.60
$6.30
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
39.5K
★ 228.0K
Earning Date
04-24-2026
10-23-2026
Dividend Yield
★ 6.53%
N/A
EPS Growth
N/A
N/A
EPS
★ 0.08
N/A
Revenue
★ $98,595,651.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
★ $268.71
$446.57
Revenue Growth
N/A
N/A
52 Week Low
$18.50
$5.13
52 Week High
$42.38
$51.33

Technical Indicators

Market Signals
Indicator
MSB
NNNN
Relative Strength Index (RSI) 33.19 43.64
Support Level N/A $5.13
Resistance Level $24.64 $6.95
Average True Range (ATR) 1.28 0.52
MACD -0.08 0.21
Stochastic Oscillator 16.81 66.48

Price Performance

Historical Comparison
MSB
NNNN

About MSB Mesabi Trust

Mesabi Trust operates as a royalty trust in the United States. The company is involved in the conservation and protection of its assets. The company's principally wholly-owned segment is the iron ore mining segment, which generates income from the Peter Mitchell Mine, an iron mine located near Babbitt, Minnesota, at the northeastern end of the Mesabi Iron Range.

About NNNN Anbio Biotechnology Class A Ordinary Shares

Anbio Biotechnology is a medical device company focused on in vitro diagnostics. The company's mission is to change the diagnostics market by personalizing and decentralizing the current diagnostic solutions for faster diagnosis to improve patient prognosis. The company proposes this by providing accessible and affordable diagnostic solutions globally at the forefront of science and offering laboratory, wellness, at-home, and point-of-care (POCT) in vitro diagnostic (IVD) solutions. The business planning is to focus on validating and commercializing the existing portfolio of in vitro diagnostic products, as well as generating additional data required to support regulatory submissions and compliance, including under frameworks such as the In Vitro Diagnostic Regulation (IVDR).

Share on Social Networks: